Daiichi Sankyo Company, Limited · TSE:4568

Daiichi Sankyo — Q2 FY2010 Earnings Presentation

19 slides from Daiichi Sankyo's earnings presentation, Nov 1, 2010

  1. Slide 1: Results for Q2 FY2010

    Results for Q2 FY2010 (April 1 – September 30, 2010) November 1, 2010 President and CEO Joji Nakayama

  2. Slide 2: Results Overview

    Results Overview

  3. Slide 3: Overview of FY2010 Q2 YTD Results

    Overview of FY2010 Q2 YTD Results (Billions of yen) Net Sales (Billions of yen) Operating Income 500.0 100.0 498.9 90.1 400.0 470.6 75.0 300.0 50.0 50.9 200.0 100.0 25.0 0.0 0.0 FY2009 Q2YTD FY2010 Q2YTD FY2009 Q2YTD FY2010 Q2YTD (Billions of yen) Ordinary Income (Billions of yen) Net Income 100.0 6

  4. Slide 4: Overview of FY2010 Q2 YTD Results - compared with FY2009 Q2 YTD

    Overview of FY2010 Q2 YTD Results - compared with FY2009 Q2 YTD - Note: Figures of Ranbaxy are pre-adjusted before consolidation ４

  5. Slide 5: Year-on-Year Comparisons

    Year-on-Year Comparisons 1. Net Sales ¥498.9 billion (+¥28.3 billion, +6.0%) „Positive factors ・ Ranbaxy contribution centering on Valacyclovir (+¥32.4 billion) ・ Olmesartan (+¥6.2 billion), Loxonin (+¥3.2 billion) ・ Milestone payment received on the approval of Denosumab in Europe „Negative factors

  6. Slide 6: Year-on-Year Comparisons

    Year-on-Year Comparisons 3. Ordinary Income ¥92.6 billion (+¥40.4 billion, +77.3%) „Non-operating income ・Ranbaxy-related loss on valuation of derivatives, etc. (-¥2.9 billion) „Non-operating expenses ・ Ranbaxy-related forex losses, etc. (-¥7.1 billion) 4. Net Income ¥52.2 billion (¥33.5 billion, +1

  7. Slide 7: Outline of FY2010 Q2 YTD Results - compared with forecast

    Outline of FY2010 Q2 YTD Results - compared with forecast - ７

  8. Slide 8: FY2010 Revised Forecast

    Billions of yen, ratio to sales) Original Revised YoY Forecast Forecast Main Factors o aw Positive Factors:+18.0 Increased sales of Ranbaxy, Luitpold, and others Negative Factors: Forex impact -18.0 Forex impact:-2.0 Cost of Sales Increased costs from higher sales:+4.0 SG&A Forex impact:-9.0 expense

  9. Slide 9: Memo

    © Daiichi-Sankyo

  10. Slide 10: Second MTP: Regional Business Strategies

    Second MTP: Regional Business Strategies Japan United States z Reinforce and expand innovative and established z Target sales of $3.5 billion pharmaceuticals and vaccine businesses (Secure 1% of prescription drugs market) Hybrid Business Model Europe ASCA * z Target sales of 1.2 billion euros z Targ

  11. Slide 11: Bolstering Our Domestic Presence: Innovative Pharmaceuticals

    Bolstering Our Domestic Presence to Become Japan’s Top Company Innovative Pharmaceuticals: Maximize New Products New Domestic Prescription Pharmaceuticals in Fiscal 2010 Rezaltas <Antihypertensive> Launched on April 16, 2010 Loxonin Gel <Anti-inflammatory and analgesic> Launched on October 5, 2010 I

  12. Slide 12: Established Pharmaceuticals and Vaccine Business

    Bolstering Our Domestic Presence to Become Japan’s Top Company Established Pharmaceuticals Launching Daiichi Sankyo Espha operations (October 1, 2010) ・ Network of around 70 medical representatives in 12 areas nationwide ・ Products: Long-listed, off-patent pharmaceuticals - 19 products consisting of

  13. Slide 13: Status of Major Business Units

    Status of Major Business Units １３ Note: We do not revise forecasts by specific business units.

  14. Slide 14: Sales of Major Products

    Sales of Major Products Note: We do not revise forecast by product line. *1 We have excluded forex factors from progress rates for global and overseas products. １４ *2 We do not disclose forecast of prasugrel.

  15. Slide 15: R&D Pipeline Update

    R&D Pipeline Update

  16. Slide 16: R&D Pipeline Progress since July 2010

    R&D Pipeline Progress since July 2010 Stage progress ● Application→ Approval CS-8958: Laninamivir, anti-influenza, treatment (JPN) • Brand name: Inavir® Dry Powder Inhaler 20mg Levofloxacin Injection: fluoroquinolone (JPN) • Brand name: Cravit® intravenous drip infusion ● Phase III → Application AMG

  17. Slide 17: Development Pipeline

    Development Pipeline Phase 1 Phase 2 Phase 3 Application - Prasugrel (ACS-MM) - Edoxaban (JPN) Cardiovascular diseases - DB-772d - Edoxaban (AF/VTE) - CS-8635 (EU) Diabetes mellitus - CS-1036 - ARQ 197 - Tigatuzumab Malignant neoplasm - CS-7017 - Nimotuzumab (#) - U3-1287 - CS-4771 Infectious diseas

  18. Slide 18: Reference: FY2010 Daiichi Sankyo Briefings

    Reference: FY2010 Daiichi Sankyo Briefings Date (JST) Ranbaxy November 11, 2010 2010 Q3 Financial Results December 10, 2010 R&D Meeting 9:30- Keidanren Kaikan January 31, 2011 FY2010 Q3 Financial Results ( Conference Call ) １８

  19. Slide 19: Corporate Communications Department

    Contact address regarding this material DAIICHI SANKYO CO., LTD. Corporate Communications Department TEL: +81-3-6225-1126 Public Relations +81-3-6225-1125 Investor Relations FAX: +81-3-6225-1132 Each numerical value regarding the future prospect in this material is derived from our judgment and assu

Daiichi Sankyo Company — Q2 FY2010 Earnings Presentation on 6ix